APLT
Income statement / Annual
Last year (2024), Applied Therapeutics, Inc.'s total revenue was $455.00 K,
a decrease of 95.45% from the previous year.
In 2024, Applied Therapeutics, Inc.'s net income was -$105.62 M.
See Applied Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$455.00 K |
$9.99 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$425.00 K
|
$353.00 K
|
$441.00 K
|
$415.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$30.00 K
|
$9.64 M
|
-$441.00 K
|
-$415.00 K
|
-$380.00 K
|
-$23.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.07
|
0.96
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$48.74 M
|
$53.91 M
|
$55.63 M
|
$62.57 M
|
$61.79 M
|
$32.35 M
|
$11.47 M
|
$3.70 M
|
| General & Administrative Expenses |
$56.01 M
|
$20.62 M
|
$27.32 M
|
$43.05 M
|
$32.68 M
|
$13.23 M
|
$2.05 M
|
$582.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$56.01 M
|
$20.62 M
|
$27.32 M
|
$43.05 M
|
$32.68 M
|
$13.23 M
|
$2.05 M
|
$582.00 K
|
| Other Expenses |
-$48.74 M
|
-$53.91 M
|
-$177.00 K
|
-$521.00 K
|
$0.00
|
$0.00
|
-$1.14 M
|
$0.00
|
| Operating Expenses |
$104.75 M
|
$74.53 M
|
$82.95 M
|
$105.62 M
|
$94.47 M
|
$45.58 M
|
$13.52 M
|
$4.29 M
|
| Cost And Expenses |
$104.75 M
|
$74.53 M
|
$82.95 M
|
$105.62 M
|
$94.47 M
|
$45.58 M
|
$13.52 M
|
$4.29 M
|
| Interest Income |
$3.53 M
|
$1.37 M
|
$685.00 K
|
$555.00 K
|
$559.00 K
|
$93.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$555.00 K
|
$559.00 K
|
$93.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$426.00 K
|
$353.00 K
|
$441.00 K
|
$415.00 K
|
$380.00 K
|
$23.00 K
|
$13.52 M
|
$4.29 M
|
| EBITDA |
-$103.87 M |
-$64.53 M |
-$82.07 M |
-$105.17 M |
-$94.47 M |
-$45.58 M |
-$3.00 M |
$3.00 K |
| EBITDA Ratio |
-228.29
|
-6.46
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-229.23
|
-6.46
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.33 M
|
-$55.23 M
|
$442.00 K
|
$34.00 K
|
$505.00 K
|
$69.00 K
|
-$3.00 M
|
$3.00 K
|
| Income Before Tax |
-$105.62 M
|
-$119.76 M
|
-$82.51 M
|
-$105.58 M
|
-$93.96 M
|
-$45.51 M
|
-$16.52 M
|
-$4.28 M
|
| Income Before Tax Ratio |
-232.14
|
-11.98
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$819.00 K
|
-$970.00 K
|
-$939.00 K
|
-$116.00 K
|
$4.87 M
|
-$4.29 M
|
| Net Income |
-$105.62 M
|
-$119.76 M
|
-$82.51 M
|
-$105.58 M
|
-$93.96 M
|
-$45.51 M
|
-$16.52 M
|
-$4.28 M
|
| Net Income Ratio |
-232.14
|
-11.98
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.76 |
-1.42 |
-2.18 |
-4.12 |
-4.28 |
-3.55 |
-1.8 |
-0.47 |
| EPS Diluted |
-0.76 |
-1.42 |
-2.18 |
-4.12 |
-4.28 |
-3.55 |
-1.8 |
-0.47 |
| Weighted Average Shares Out |
$139.54 M
|
$84.24 M
|
$37.83 M
|
$25.60 M
|
$21.97 M
|
$12.83 M
|
$9.16 M
|
$9.16 M
|
| Weighted Average Shares Out Diluted |
$139.54 M
|
$84.24 M
|
$37.83 M
|
$25.60 M
|
$21.97 M
|
$12.83 M
|
$9.16 M
|
$9.16 M
|
| Link |
|
|
|
|
|
|
|
|
